EPIDIOLEX® (cannabidiol) offers flexible dosing for tolerability and response optimization
Calculate your patient's dosage by selecting a recommended dose below or entering a custom dose
RECOMMENDED DOSING AND TITRATION
Increase in weekly increments of 5 mg/kg/day (2.5 mg/kg twice daily)*
Week 1
(2.5 mg/kg twice daily)
Week 2
(5 mg/kg twice daily)
Week 3
(7.5 mg/kg twice daily)
Week 4
(10 mg/kg twice daily)
Week 5
(12.5 mg/kg twice daily)
LGS
& DS
TSC
Dose adjustment and a slower dose titration are recommended in patients with moderate or severe hepatic impairment. Select an option above to view dosing recommendations for patients with hepatic impairment.
DS=Dravet syndrome.
*For patients in whom a more rapid titration is warranted, the dosage may be increased no more frequently than every other day.
†For patients with LGS or Dravet syndrome, administration of the 20 mg/kg/day dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions. Increase dose from 10 mg/kg/day if tolerated and required.
‡The effectiveness of doses lower than 25 mg/kg/day has not been studied in patients with TSC.
Because of an increase in exposure to EPIDIOLEX, dose adjustment and slower titration are recommended in patients with moderate or severe hepatic impairment. Consider not initiating EPIDIOLEX in patients with evidence of significant liver injury. Dose adjustments are not required in patients with mild hepatic impairment.
Review additional monitoring considerations
RECOMMENDED DOSAGE AND TITRATION — 1/2 STANDARD DOSING*
Week 1
(1.25 mg/kg twice daily)
Week 2
(2.5 mg/kg twice daily)
Week 3
(3.75 mg/kg twice daily)
Week 4
(5 mg/kg twice daily)
Week 5
(6.25 mg/kg twice daily)
LGS
& DS
TSC
DS=Dravet syndrome.
*NOTE: Total dosage should be split and administered twice daily. See additional dosing considerations for more information.
Because of an increase in exposure to EPIDIOLEX, dose adjustment and slower titration are recommended in patients with moderate or severe hepatic impairment. Consider not initiating EPIDIOLEX in patients with evidence of significant liver injury. Dose adjustments are not required in patients with mild hepatic impairment.
Review additional monitoring considerations
RECOMMENDED DOSAGE AND TITRATION — 1/5 STANDARD DOSING*
Week 1
(0.5 mg/kg twice daily)
Week 2
(1 mg/kg twice daily)
Week 3
(1.5 mg/kg twice daily)
Week 4
(2 mg/kg twice daily)
Week 5
(2.5 mg/kg twice daily)
LGS
& DS
TSC
DS=Dravet syndrome.
*NOTE: Total dosage should be split and administered twice daily. See additional dosing considerations for more information.
Please ensure the weight you entered is correct.
Download the EPIDIOLEX dosing calculator app for your mobile device
Other dosing considerations
- Food may affect EPIDIOLEX levels: EPIDIOLEX is an oral solution that is compatible with a ketogenic diet. EPIDIOLEX should be administered consistently with respect to meals. If necessary, EPIDIOLEX can be administered with certain nasogastric tubes (NG-tube) or gastrostomy tubes (G-tube). For specific instructions, please see the EPIDIOLEX Prescribing Information.
- EPIDIOLEX can cause dose-related elevations of liver transaminases: Because of the risk of hepatocellular injury, obtain serum transaminases (ALT and AST) and total bilirubin levels in all patients prior to starting treatment with EPIDIOLEX and periodically thereafter.
- Because of an increase in exposure to EPIDIOLEX, dose adjustment and slower dose titration are recommended in patients with moderate or severe hepatic impairment. Consider not initiating EPIDIOLEX in patients with evidence of significant liver injury. Dose adjustments are not required in patients with mild hepatic impairment
- Taking EPIDIOLEX with other drugs: Strong inducers of CYP3A4 and CYP2C19 may affect EPIDIOLEX exposure. EPIDIOLEX may affect exposure to CYP2C19 substrates (e.g., clobazam, diazepam, stiripentol), orally administered P-gp substrates, or other substrates (see full Prescribing Information). Consider dose reduction of orally administered everolimus, with appropriate therapeutic drug monitoring, when everolimus is combined with EPIDIOLEX. A lower starting dose of everolimus is recommended when added to EPIDIOLEX therapy. Concomitant use of EPIDIOLEX and valproate increases the incidence of liver enzyme elevations. Pneumonia was observed more frequently with concomitant use of EPIDIOLEX and clobazam. Dosage adjustment of EPIDIOLEX or other concomitant medications may be necessary.
CONSIDERATIONS
Administering EPIDIOLEX
Step-by-step instructions for administration.
Administering EPIDIOLEX
Step-by-step instructions for administration
Writing a prescription
This is provided for example purposes only. Not intended to supersede independent clinical judgment or institutional protocols. Please see full Prescribing Information for recommendations on liver monitoring.
As certain health plans and institutions may have policies regarding cannabinoid products/use, prescriptions should include EPIDIOLEX by name to avoid rejection.
If dose adjustment is required mid-prescription cycle, a new prescription will be needed.
This is provided for example purposes only. Not intended to supersede independent clinical judgment or institutional protocols. Please see full Prescribing Information for recommendations on liver monitoring.
Writing a prescription? Look up specialty pharmacies in your area that
provide EPIDIOLEX
